Business
Satellite Symposium at EAACI 2017
Satellite Symposium at EAACI 2017.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 3866I Allergy Therapeutics PLC 19 June 2017 \n\n \n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Group\")\n \nAllergy Therapeutics hosts satellite symposium at EAACI 2017\n \n~ World-leading experts discuss allergy immunotherapies ~\n \nAllergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces today that a satellite symposium entitled: \"The Best Therapies by Design\" was held at the 36th Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Helsinki, Finland on 18 June 2017, providing an overview of the technologies and strategies involved in designing the best immunotherapies.\n \nChaired by Professor Stephen Durham, four world-leading experts in the field of allergy, pollen, and immunotherapy vaccine delivery, Jörg Kleine-Tebbe, Erika Jensen-Jarolim, Uwe Berger & Tim Higenbottam presented on the strategy, design and considerations involved in creating immunotherapies such as Allergy Therapeutics' flagship product, Pollinex Quattro®. Uwe Berger and Erika Jensen-Jarolim discussed the importance of highlighting relevant allergens and characterising them sufficiently. Jörg Kleine-Tebbe discussed why successful immunotherapy requires identification of the optimal dose before Phase III studies are begun, before Tim Higenbottam finished the session describing the results recently gained from the Group's clinical studies.\n \nManuel Llobet, Chief Executive Officer, commented: \"We are delighted with our progress in developing the next generation of allergen immunotherapy products. Our latest clinical data on dose-ranging confirms that our unique allergen-specific immunotherapies are formulated to the optimal strength and we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free products.\"\nSatellite Symposium: \"The Best Therapies by Design\"\n1. The importance of defining the optimal dose - Jörg Kleine-Tebbe, Allergie und Asthma - Zentrum Westend, Berlin.\n2. Molecular fingerprinting of complex allergoids - Erika Jensen-Jarolim, Institute of Pathophysiology and Allergy Research, Medical Unive...